Holdings

PSP Research LLC

As of Sep 30, 2026, PSP Research LLC reported 40 positions worth US$145M. Largest: iShares 0-3 Month Treasury Bond ETF, State Street SPDR S&P Biotech ETF and Sera Prognostics, Inc. What it bought and sold, with each filing.

Holdings

Positions
40
Value as reported
US$145M
Holdings as of
Sep 30, 2026
Last filed
Oct 21, 2026
CompanySharesValue as reported% of company% of portfolioChangeAs of
iShares 0-3 Month Treasury Bond ETF
NYSE:SGOV
700KUS$70.5M48.3%NewSep 30, 2026
State Street SPDR S&P Biotech ETF
AMEX:XBI
387KUS$60.9M41.8%NewSep 30, 2026
Sera Prognostics, Inc.
NASDAQ:SERA
2.4MUS$5.01M6.2%3.4%NewSep 30, 2026
Halozyme Therapeutics, Inc.
NASDAQ:HALO
3,000US$331K0.23%−4,000Sep 30, 2026
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
600US$302K<0.01%0.21%No changeSep 30, 2026
Exelixis, Inc.
NASDAQ:EXEL
5,000US$292K0.20%−3,000Sep 30, 2026
argenx SE
EURONEXT:ARGX
300US$288K0.20%−341Sep 30, 2026
Nurix Therapeutics, Inc.
NASDAQ:NRIX
12,000US$285K0.20%−13,000Sep 30, 2026
TG Therapeutics, Inc.
NASDAQ:TGTX
5,000US$279K<0.01%0.19%−5,000Sep 30, 2026
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
3,500US$275K0.19%−3,500Sep 30, 2026
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
7,000US$275K0.01%0.19%−3,000Sep 30, 2026
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
10,000US$264K0.18%−9,700Sep 30, 2026
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
6,000US$258K0.01%0.18%No changeSep 30, 2026
Immunome, Inc.
NASDAQ:IMNM
12,000US$258K0.18%−6,000Sep 30, 2026
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
1,800US$255K0.18%−1,200Sep 30, 2026
Oruka Therapeutics, Inc.
NASDAQ:ORKA
3,000US$250K0.17%No changeSep 30, 2026
Tango Therapeutics, Inc.
NASDAQ:TNGX
10,000US$250K0.17%No changeSep 30, 2026
Definium Therapeutics, Inc.
NASDAQ:DFTX
6,500US$247K<0.01%0.17%−3,500Sep 30, 2026
Revolution Medicines, Inc.
NASDAQ:RVMD
1,200US$246K<0.01%0.17%No changeSep 30, 2026
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
15,000US$243K0.01%0.17%−15,000Sep 30, 2026
Incyte Corporation
NASDAQ:INCY
2,000US$243K<0.01%0.17%−3,300Sep 30, 2026
Intellia Therapeutics, Inc.
NASDAQ:NTLA
20,000US$241K0.01%0.17%No changeSep 30, 2026
Immunovant, Inc.
NASDAQ:IMVT
7,000US$236K<0.01%0.16%−6,000Sep 30, 2026
Stoke Therapeutics, Inc.
NASDAQ:STOK
9,000US$234K0.16%−3,000Sep 30, 2026
Krystal Biotech, Inc.
NASDAQ:KRYS
692US$230K<0.01%0.16%No changeSep 30, 2026
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
12,000US$226K0.15%−8,000Sep 30, 2026
Kymera Therapeutics, Inc.
NASDAQ:KYMR
2,000US$224K0.15%−2,000Sep 30, 2026
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
2,500US$220K0.15%No changeSep 30, 2026
Trevi Therapeutics, Inc.
NASDAQ:TRVI
15,000US$215K0.15%−15,000Sep 30, 2026
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
2,500US$214K0.15%No changeSep 30, 2026
Immunocore Holdings plc
NASDAQ:IMCR
7,000US$212K0.01%0.15%NewSep 30, 2026
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
1,500US$211K0.14%−1,500Sep 30, 2026
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
5,000US$203K0.14%No changeSep 30, 2026
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
13,000US$175K0.12%No changeSep 30, 2026
Dyne Therapeutics, Inc.
NASDAQ:DYN
10,000US$161K0.11%−10,000Sep 30, 2026
COMPASS Pathways Plc
NASDAQ:CMPS
10,000US$124K<0.01%0.09%NewSep 30, 2026
Ocular Therapeutix, Inc.
NASDAQ:OCUL
15,000US$115K<0.01%0.08%No changeSep 30, 2026
CytomX Therapeutics, Inc.
NASDAQ:CTMX
39,400US$107K0.02%0.07%No changeSep 30, 2026
Ardelyx, Inc.
NASDAQ:ARDX
30,000US$103K0.01%0.07%−30,000Sep 30, 2026
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
10,000US$86,4000.06%No changeSep 30, 2026